tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Twist Bioscience narrows FY25 revenue view to $374M-$376M from $372M-$379M

Consensus $376.21M. Raises FY25 adjusted EBITDA loss view to $45M-$47M from $48M-$53M. Gross margin is projected to be approximately 50.5% to 51.0%.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1